Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Inclusion Criteria: * Subjects, \>= 18 years old, must have a histologically confirmed diagnosis of sarcomas of the extremities (which may include gluteal muscle involvement) for which neoadjuvant radiation therapy followed by surgical resection is a planned intervention * Subjects whose bowel cannot be completely protected from radiation exposure due to primary tumor location (e.g., proximal lower extremity) will be excluded * Subjects must have one or more measurable target lesions by RECIST version (v) 1.1, assessed via computed tomography (CT) scan or magnetic resonance imaging (MRI) * At the time of study enrollment, subjects must have a tumor burden that is judged to be surgically resectable * Absolute neutrophil count (ANC) \>= 1500/mm\^3 (\>= 1.5 GI/L) without granulocyte colony-stimulating factor support in the last 28 days * White blood cell count \>= 2500/mm\^3 (\>= 2.5 GI/L) * Platelets \>= 100,000/mm\^3 (\>=100 GI/L) without transfusion in the last 28 days * Hemoglobin \>= 9 g/dL (\>= 90 g/L) without transfusion in the last 28 days * Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =\< 3 X upper limit of normal (ULN) * Alkaline phosphatase (ALP) =\< 3 X upper limit of normal (ULN) * ALP =\< 5 X ULN is permitted in subjects with documented bone metastases (phase 1 only) * Total bilirubin =\< 1.5 x ULN (for subjects with Gilbert's disease =\< 3 X ULN) * Serum albumin \>= 2.8 g/dl * Serum creatinine =\< 2.0 x ULN or calculated creatinine clear…